M
Monica Bellei
Researcher at University of Modena and Reggio Emilia
Publications - 68
Citations - 5009
Monica Bellei is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Follicular lymphoma & ABVD. The author has an hindex of 25, co-authored 66 publications receiving 4364 citations. Previous affiliations of Monica Bellei include University of Wisconsin-Madison.
Papers
More filters
Journal ArticleDOI
Prognostic value of baseline total metabolic tumor volume (tmtv) for patients with early stage hodgkin lymphoma enrolled in the standard arm of the h10 (eortc/lysa/fil) trial
A. Cottereau,A. Versari,Annika Loft,René-Olivier Casasnovas,Monica Bellei,Romain Ricci,Stéphane Bardet,Antonio Castagnoli,Pauline Brice,John M. M. Raemaekers,Bénédicte D’Eau,Catherine Fortpied,Tiana Raveloarivahy,Theodore Girinsky,E. Van Zele,T. Vander Borght,Massimo Federico,Martin Hutchings,Umberto Ricardi,Marc André,Michel Meignan +20 more
The prognosis of follicular lymphomas: The F2-project
Massimo Federico,Monica Bellei,Barbara Pro,Armando López-Guillermo,Umberto Vitolo,Stefano Luminari,S. A. Pileri,Philippe Solal-Celigny +7 more
TL;DR: Follicular lymphoma (FL) accounts for 10 to 15% of non-Hodgkin's lymphomas in western countries as mentioned in this paper, however, criteria to rationalize treatment decisions are still lacking in many instances.
Journal ArticleDOI
Autologous stem cell transplantation as part of first‐line therapy in patients with peripheral t‐cell lymphoma: a multicenter geltamo/fil study
Miriam López-Parra,Monica Bellei,Alessandro Rambaldi,Silvana Novelli,Carlos Panizo,Marialuisa Martelli,I. Dhouly,Mariana Bastos,Antonio Gutierrez,Juan-Manuel Sancho,Manuel Ramírez,José-María Moraleda,E. Carrillo Cruz,A. Jiménez Ubieto,Isidro Jarque,U. Vittolo,N. de las Heras,Reyes Arranz,Javier López-Jiménez,Carlos Montalbán,María Jesús Pascual,Paolo Corradini,S. Bobillo,G. Estefania,Michele Spina,Giulio Rossi,Martina Manni,Massimo Federico,Dolores Caballero,A. Martín +29 more
TL;DR: It is demonstrated that the incidence rate of BIA-ALCL may be higher than previously reported, and this results can help inform implant choice for women undergoing breast reconstruction.
Journal ArticleDOI
Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study
Emilio Iannitto,Monica Bellei,Andrés J.M. Ferreri,Luigi Marcheselli,Marina Cesaretti,Corinne Haioun,Salvatrice Mancuso,Krimo Bouabdallah,Remy Gressin,Claudio Tripodo,Alexandra Traverse-Glehen,Lucile Baseggio,Simonetta Zupo,Caterina Stelitano,Barbara Castagnari,Caterina Patti,Francesco Merli,Anna Marina Liberati,Michele Merli,Guido Gini,Maria Giuseppina Cabras,Jehan Dupuis,Francesca Re,Emanuele Zucca,Massimo Federico,Catherine Thieblemont +25 more
TL;DR: Bendamustine in association with Rituximab is effective and well tolerated as first line immuno-chemotherapy regimen for non splenectomised SMZL patients, and the favorable toxicity profile suggests the choice of this regimen is deemed to be used for high risk, heavily symptomatic non splanectomized SMzL patients.
Transformed Follicular Lymphoma: Not all fit in one
Vittoria Tarantino,Luana Conte,Martina Manni,Alessandra Dondi,Monica Bellei,Massimo Federico +5 more
TL;DR: The present review describes the state of art of tFL, outlining recent advances in the understanding of genetic basis and the evolutionary pro-cess governing the initiation and persistence of tumor evolution.